Core Biogenesis, a France-based upcoming biotechnology firm offering a plant-based bioproduction platform has raised USD 10.5 million in a Series A funding round led by XAnge with participation from Blue Horizon Ventures and Thia Ventures.
The funds are expected to be used for building an industrial-scale facility dedicated toward the production of growth factors and cytokines for the burgeoning cell therapy and cellular agriculture industry. Furthermore, it will be used for additional scientific and technical staff hires to aid expansion.
Core Biogenesis, founded in 2020 offers a novel green bioproduction platform for deriving plant-based recombinant proteins from the Camelina sativa oilseed plant. The company claims its patent-pending technology and animal-free growth factors allow for a more cost-effective and commercially viable cell therapy manufacturing process and can be used for a wide array of applications from therapeutics to cultivated meat.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.